Immutep (ASX:IMM) has passed a key clinical milestone, achieving 50 per cent patient enrolment in its pivotal global Phase 3 trial evaluating a novel immunotherapy combination for first-line non-small cell lung cancer. …
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 17 April
April 17, 2026 - - Podcast -
Australia, the US, and their different choices about health system trade-offs
April 17, 2026 - - Latest News -
Why hospitals, and not medicines, dominate America’s health spending gap
April 17, 2026 - - Latest News -
New strategic alliance for Biointelect aims to fast track life sciences innovation
April 17, 2026 - - Latest News -
Mark Butler confirms new and expanded cancer medicine listings
April 17, 2026 - - Latest News -
Why US health spending looks much higher than it really is
April 16, 2026 - - Latest News -
Pharmacy prescribing reform signals shift in NSW primary care with Victoria to follow
April 15, 2026 - - Latest News